Avon Launches Fundraiser for ALS TDI
The ALS Therapy Development Institute (ALS TDI) and the Avon Products, Inc. (Avon) announced today a fundraising campaign to fund research into effective treatments for ALS (Lou Gehrig's disease). The campaign includes the production of a new item called the "Sophia Smith Yellow Rose Necklace" being added to its catalog and with all proceeds going to support research at ALS TDI.
Sophia Smith of Victoria, Texas, started part-time with Avon in 1986 and quickly excelled as a sales Representative, becoming a senior executive and member of the Avon sales leadership team in 1992. She is a mother of three and an avid motorcyclist. In November 2010, Sophia was diagnosed with ALS. Currently, there are no effective treatments or cure for the disease.
"Sophia has always been an inspiring member of the Avon family and it was heartbreaking for all of us to learn of her ALS diagnosis. Tragically, a cure for this debilitating disease may not come in time to help Sophia, but she wants to ensure that others have a fighting chance. We are taking a stand with her and are supporting Sophia through this fundraising campaign," said Andrea Jung, chairman & CEO of Avon.
"With the help of Avon, we hope to build awareness and accelerate the pace of research to find an effective treatment for ALS patients. Sophia is an inspiration, her strength and courage is admired by those around her," said Steve Perrin, Ph.D., president, CEO and CSO of the ALS Therapy Development Institute.
Each necklace costs $9.99 and can be purchased through an Avon Representative or online by clicking "fundraising" at www.avon.com starting today. The necklaces will be available for a limited time only.
About ALS Therapy Development Institute The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically validate potential therapeutics; including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only nonprofit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development.
More Avon news
Avon Products U.S. Debtors File Chapter 11 Liquidation Plan
The U.S. debtors in the Avon Products Chapter 11 case, now known as AIO US, Inc. and affiliates, filed a Chapter 11 plan of liquidation and a disclosure statement in the U.S....
Avon North America Moves Ambassadors to Variable Commission Plan for 2025
NEW YORK, New York -- December 11, 2024 The Avon Company, Avon's North American business, will move its Avon Ambassadors to a new commission structure effective January 1, 2025....
Bankruptcy Court Approves Avon Sale Procedures With Parent Natura as Stalking Horse Bidder
The U.S. Bankruptcy Court for the District of Delaware on October 29, 2024 entered an order approving bidding procedures for the sale of substantially all of the assets of Avon...
Avon Promotes Europe Marketing Head Ozlem Citci to Chief Marketing Officer
Avon has named Ozlem Citci chief marketing officer, filling the post weeks after former marketing chief Kristof Neirynck was promoted to chief executive of Avon International....
Regent Completes Avon North America Purchase; Lisa Siders Becomes CEO
Regent completed its acquisition of The Avon Company, Avon North America, from LG Household & Health Care on September 1, 2026, reuniting the U.S. and Canada business with Avon...